Mercado global de testes genéticos de doenças raras – Tendências do setor e previsão para 2029

Análise e dimensão do mercado de testes genéticos de doenças raras

O teste genético é um tipo de exame médico que deteta alterações nos genes, cromossomas ou proteínas. Os resultados de um teste genético podem confirmar uma suspeita de condição genética ou podem ajudar a determinar o risco de uma pessoa desenvolver ou transmitir uma doença genética. A maioria dos testes é utilizada para diagnosticar doenças genéticas raras , como a Distrofia Muscular de Duchenne e a Síndrome do X Frágil. Os testes genéticos são realizados numa amostra de sangue, líquido amniótico (o líquido que envolve o feto durante a gravidez) ou outro tecido. No caso dos recém-nascidos, os testes de rastreio genético são feitos a partir de uma pequena amostra de sangue obtida através de uma picada no calcanhar do bebé.

A Data Bridge Market Research analisa que o mercado de testes genéticos de doenças raras, que foi de 785,8 milhões de dólares em 2021, deverá atingir 1.982,04 milhões de dólares até 2029, com um CAGR de 12,26% durante o período de previsão de 2022 a 2029. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research também incluem análise especializada aprofundada, epidemiologia de doentes, análise de pipeline, análise de preços e enquadramento regulamentar.

Âmbito e segmentação do mercado de testes genéticos de doenças raras      

Market Definition

Genetic testing is a diagnostic tool that not only aids in the identification of specific disease manifestations but also in determining the underlying causes of genetic disorders. Genetic testing has a variety of advantages such as confirming a diagnosis, determining the cause of unexplained symptoms, and identifying treatment options, including clinical trials. Genetic testing refers to a wide range of applications, ranging from family history collection and evaluation to whole genome screening. Each test has its own set of advantages and disadvantages based on the technology used and the indication for the test. A rare disease refers to a condition, disorder or disease that affects a small percentage of the population at any given time. For instance, in the European Union, it affects fewer than 1 in 2,000 individuals, in the United States, a rare disease is defined as a disease that affects less than 200,000 individuals.

Global Rare Disease Genetic Testing Market Dynamics

Drivers

• Genetic testing use in research laboratories

Genetic testing is used in the research laboratories for laboratory test to look for variations in an individual's DNA, typically in the context of medical care, ancestry studies, or forensics. A genetic test's results can be used in a medical setting to confirm a suspected genetic disease. Genetic testing is the use of a laboratory test to examine an individual’s DNA for variations, typically performed in the context of ancestry studies, forensics, medical care. These all are the certain factors which propel the growth of market.

• Rise in diagnostic testing

Diagnostic testing is used to identify a specific genetic or chromosomal condition. In many cases, genetic testing is used to confirm a diagnosis when a particular condition is suspected based on physical signs and symptoms. Even though uncovering the genetic cause behind a condition may not directly impact treatment options, it will provide physicians and the families with useful information. For instance, physicians can combine genetic testing with existing clinical and biochemical analyses to accurately confirm a disease diagnosis. These are the factors which boost the market’s growth.

Opportunities

• Rise in disease testing

The Canadian organization for rare disorders (CORD) provides a strong platform for streamlining health policy and a healthcare system dedicated to the management of patients with disorders. The agency works with clinicians, researchers, governments and the diagnostic industry to advance research and development, diagnosis, treatment, and service availability for all rare conditions in the country. According to the National Institutes of Health (NIH), approximately 30 million Americans have been diagnosed with one of the 7,000+ known rare diseases. With increased awareness, the number of patients undergoing disease testing is expected to rise in the coming years.

Restraints/Challenges

• Dearth of trained healthcare personnel

Lack of regulatory framework in emerging economies associated with dearth of trained healthcare personnel will obstruct the market's growth rate.

This rare disease genetic testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the rare disease genetic testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Rare Disease Genetic Testing Market

Patients with undiagnosed and rare diseases have faced significant health challenges as a result of the COVID-19 pandemic. According to a study published in January 2021 by a group of researchers from the United States, there is an urgent need for the development of approaches that can reduce the serious challenges faced by patients and families with rare and undiagnosed diseases. The difficulties include diagnostic or prognostic uncertainty, as well as medical complexity, which leads to poor health outcomes. Furthermore, the COVID-19 pandemic had an impact on clinical trials focusing on rare diseases. Clinical trials have faced several challenges as a result of the pandemic. The difficulties in locating, recruiting, and retaining patients with rare diseases had a significant impact on clinical trials.

Recent developments

• In December 2020, Cell ID Pte. Ltd., a Singapore-based company that manufactures genetic testing products, will launch the Quiz PCR Biochip, a portable genetic test for COVID-19. This is a portable palm-sized moveable genetic test kit that uses an app to determine whether or not a person has COVID-19. This device also included a QR code for tracking purposes. The device employs pooled screening technology. This is easily portable and can conduct tests at any time
• In January 2022, Exact Sciences, a US-based manufacturer of genetic testing tools and a molecular diagnostics company acquired Prevention Genetics for $190 million. Exact Sciences hopes to increase hereditary cancer testing for more patients as a result of this acquisition

Global Rare Disease Genetic Testing Market Scope

The rare disease genetic testing market is segmented on the basis of disease type, technology, speciality, end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Neurological Disorders
• Immunological Disorders
• Hematology Diseases
• Endocrine
• Metabolism Diseases
• Cancer
• Musculoskeletal Disorders
• Cardiovascular Disorders (CVDs)
• Dermatology Disease
• Others

Technology

• Next-Generation Sequencing (NGS)
• Whole Exome Sequencing
• Whole Genome Sequencing
• Array Technology
• PCR-based Testing
• FISH
• Sanger Sequencing
• Karyotyping

Specialty

• Molecular Genetic Tests
• Chromosomal Genetic Tests
• Biochemical Genetic Tests

 End Use

• Research Laboratories
• CROs
• Diagnostic Centers
• Hospitals
• Clinics

Rare Disease Genetic Testing Market Regional Analysis/Insights

The rare disease genetic testing market is analysed and market size insights and trends are provided by country, disease type, technology, speciality, end-user as referenced above.

Os países abrangidos no relatório de mercado Testes genéticos para doenças raras são os EUA, Canadá e México na América do Norte, Alemanha, França, Reino Unido, Holanda, Suíça, Bélgica, Rússia, Itália, Espanha, Turquia, Resto da Europa na Europa, China, Japão , Índia, Coreia do Sul, Singapura, Malásia, Austrália, Tailândia, Indonésia, Filipinas, Resto da Ásia-Pacífico (APAC) na Ásia-Pacífico (APAC), Arábia Saudita, Emirados Árabes Unidos, África do Sul, Egito , Israel, Resto do Médio Leste e África (MEA) como parte do Médio Oriente e África (MEA), Brasil, Argentina e Resto da América do Sul como parte da América do Sul.

A América do Norte domina o mercado de testes genéticos para doenças raras devido ao grande número de registos de doenças raras e à presença de um número considerável de atividades de I&D para doenças raras e ultra-raras.

Espera-se que a Ásia-Pacífico cresça à maior taxa de crescimento no período de previsão de 2022 a 2029 devido à crescente consciencialização e à população-alvo na região específica.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.

Análise do panorama competitivo e da quota de mercado de testes genéticos de doenças raras

O panorama competitivo do mercado de testes genéticos para doenças raras fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado de testes genéticos para doenças raras.

Alguns dos principais players que trabalham no mercado de testes genéticos para doenças raras são:

• Quest Diagnostics Incorporated (EUA)
• Centogene NV (Alemanha)
• Strand Life Sciences (Bangalore)
• Ambry Genetics (EUA)
• (EUA)
• (Coreia do Sul)
• Baylor Genetics (EUA)
• HNL Lab Medicine (EUA)
• Prevençãogenética (EUA)
• 3 biliões, Inc. (Coreia do Sul)
• Laboratórios Arup (EUA)
• HNL Lab Medicine (EUA)
•  Prevençãogenética (EUA)
• Invitae Corporation (EUA)
•  Eurofins Scientific (Luxemburgo)
•  Strand Life Sciences (Índia)
•  Realm IDX, Inc.
•  Myriad Genetics, Inc.
•  Laboratory Corporation of America Holdings (EUA)
•  (EUA)

SKU-55638